Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Chemomab Therapeutics Ltd <CMMB.OQ> expected to post a loss of 15 cents a share - Earnings Preview
Chemomab Therapeutics Ltd CMMB.OQ CMMB.O is expected to show no change in quarterly revenue when it reports results on August 12 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Chemomab Therapeutics Ltd is for a loss of 15 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Chemomab Therapeutics Ltd is $15.00, about 677.2% above its last closing price of $1.93
This summary was machine generated August 10 at 13:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Chemomab Therapeutics
See all newsBrief: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Brief: Chemomab Therapeutics Announces Nebokitug Phase 2 Spring Trial Results
Brief: Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update